[1] 饶华春, 魏思达.宫颈癌相关易感基因研究进展[J]. 河南医学研究, 2018, 27(22):4087-4089.
[2] COHEN P A, JHINGRAN A, OAKNIN A, et al. Cervical cancer[J]. The Lancet, 2019, 393(10167):169-182.
[3] PAGET S.The distribution of secondary growths in cancer of the breast[J]. The Lancet, 1889, 133(3421):571-573.
[4] NICOL A F, DE ANDRADE C V, RUSSOMANO F B, et al. HPV vaccines:their pathology-based discovery, benefits, and adverse effects[J]. Annals of Diagnostic Pathology, 2015, 19(6):418-422.
[5] STERNRODEN R, STERN P L.Opportunities and challenges for human papillomavirus vaccination in cancer[J]. Nature Reviews Cancer, 2018, 18(Suppl 5):240-254.
[6] 张梦培, 尹如铁, 李克敏, 等. 中国西部女性生殖道高危人乳头状病毒感染状况的Meta分析[J]. 中国循证医学杂志, 2019, 19(11):1268-1275.
[7] GISSMANN L, WOLNIK L, IKENBERG H, et al. Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers[J]. Proceedings of the National Academy of Sciences of the United States of America, 1983, 80(2):560-563.
[8] SELLORS J W, MAHONY L B, KACZOMWSKI J, et al. Prevalence and predietots of human papilomavirus infection in women in Ontario, Canada.Survey of HPV in Ontario Women(SHOW)Group[J]. CMAJ, 2000, 163(5):503.
[9] TSANG S H, SAMPSON J N, JOHN S, et al. Durability of cross-protection by different schedules of the bivalent HPV vaccine:the CVT trial[J]. J Nat Cancer Ins, 2020(10):1093.
[10] 李圆月.HPV感染后不同程度宫颈病变和阴道微生态关系的研究[D].昆明:昆明理工大学, 2019.
[11] RAVEL J, GAJER P, ABDO Z, et al. Vaginal microbiome of reproductive-age women[J]. Proc Natl Acad Sci U S A, 2011, 108(Suppl 1):4680-4687.
[12] ZHANG Q, CHEN R, ZHANG L, et al. Re:the vaginal metabolome and microbiota of cervical HPV-positive and HPV-negative women:a cross-sectional analysis[J]. BJOG An International Journal of Obstetrics & Gynaecology, 2020, 127(6):113.
[13] XI Y, MIAO D, ZHANG W, et al. Role of lactobacillus in cervical cancer[J]. Cancer Management and Research, 2018(default):1219-1229.
[14] KORSHUNOV V M, KAFARSKAIA L I, BAGIROVA M S H, et al. The effect of Solco Trichovac on the vaginal microflora of patients with a papillomavirus infection assciated with a cervical intraepithelial neoplasm[J]. Zh Mikrobiol Epidemiol Immunobiol, 1994, 71(5):13.
[15] LEE J E, LEE S, LEE H, et al. Association of the vaginal microbiota with human papillomavirus infection in a Korean twin cohort[J]. PLoS One, 2013, 8(5):e63514.
[16] BROTMAN R M, SHARDELL M D, GAJER P, et al. Interplay between the temporal dynamics of the vaginal microbiota and human papillomavirus detection[J]. J Infect Dis, 2014, 210(11):1723-1733.
[17] 古萍, 姜静, 郑建英, 等. 高危HPV感染对妇女阴道乳酸杆菌的影响研究[J]. 中华医院感染学杂志, 2017, 27(20):4747-4750.
[18] 康玲, 马啸, 蔡慧华, 等. 高级别宫颈鳞状上皮内瘤变锥切手术前后阴道菌群比较研究[J]. 中国实用妇科与产科杂志, 2017, 33(9):949-954.
[19] 骆菲, 朱丽红, 韩阳, 等. 高危型HPV感染与阴道微生物组关系[J]. 中国微生态学杂志, 2019, 31(6):715-719.
[20] MITRA A, MACINTYRE D A, LEE Y S, et al. Cervical intraepithelial neoplasia disease progression is associated with increased vaginal microbiome diversity[J]. Sci Rep, 2015, 5:16865.
[21] ASTRIDE A C, KIRVIS T P, MARGARITA B R, et al. Cervical microbiome and cytokine profile at various stages of cervical cancer:a pilot study[J]. PLoS One, 2016, 11(4):e0153274.
[22] BRESHEARS L M, EDWARDS V L, RAVEL J, et al. Lactobacillus crispatus inhibits growth of Gardnerella vaginalis and Neisseria gonorrhoeae on a porcine vaginal mucosa model[J]. BMC Microbiol, 2015, 15:276.
[23] BORGDORFF H, GAUTAM R, ARMSTRONG S D, et al. Cervicovaginal microbiome dysbiosis is associated with proteome changes related to alterations of the cervicovaginal mucosal barrier[J]. Mucosal Immunol, 2015, 9(3):621-633.
[24] DOORBAR J.Host control of human papillomavirus infection and disease[J]. Best Pract Res Clin Obstet Gynaecol, 2018, 47:27-41.
[25] KHAN K N, FUJISHITA A, HIRAKI K, et al. Bacterial contamination hypothesis:a new concept in endometriosis[J]. Reproductive Medicine and Biology, 2018, 17(2):125-133.
[26] 江大琼, 沈芳, 程欣, 等. 朗格汉斯细胞与宫颈癌及HPV16 E6的关系[J]. 武汉大学学报(医学版), 2012, 33(5):746-748, 764.
[27] HU T, YANG P, ZHU H, et al. Accumulation of invariant NKT cells with increased IFN-γproduction in persistent high-risk HPV-infected high-grade cervical intraepithelial neoplasia[J]. Diagnostic Pathology, 2015, 10(20):1-10.
[28] MONNIER-BENOIT S, MAUNY F, RIETHMULLER D, et al. Immunohistochemical analysis of CD4+ and CD8+ T-cell subsets in high risk human papillomavirus-associated pre-malignant and malignant lesions of the uterine cervix[J]. Gynecologic Oncology, 2006, 102(1):22-31.
[29] WALCH-RVCKHEIM B, MAVROVA R, HENNING M, et al. Stromal fibroblasts induce CCL20 through IL6/ C / EBPβ to support the recruitment of Th17 cells during cervical cancer progression[J]. Cancer Res, 2015, 75(24):5248-5259.
[30] 唐金芝.阴道菌群、宫颈局部T细胞亚群和炎性因子改变对HPV感染的影响[D].南宁:广西医科大学, 2014.
[31] LI B, ZHANG L, ZHAO J, et al. The value of cytokine levels in triage and risk prediction for women with persistent high-risk human papilloma virus infection of the cervix[J]. Infectious Agents and Cancer, 2019, 14(1):1-12.
[32] 王小花, 喻岩, 王茹.女性宫颈HPV感染与阴道局部Th17细胞免疫功能及血清因子的关系研究[J]. 分子诊断与治疗杂志, 2020, 12(2):181-184.
[33] WINKLE S M, THROOP A L, HERBST-KRALOVETZ M M.IL-36γ augments host defense and immune responses in human female reproductive tract epithelial cells[J]. Front Microbiol, 2016, 7:955.
[34] 吕全省, 马静姝, 古彦铮, 等. IL-36γ促进人CD8+T淋巴细胞细胞因子的分泌[J]. 江苏大学学报(医学版), 2016, 26(3):193-198. |
